We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...

In this article, we are going to look at where Regeneron Pharmaceuticals ... since it requires a large amount of money for costly R&D and clinical testing. Lower rates make more funding available ...

Regeneron Pharmaceuticals Inc. closed 47.64% short of its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the ... lawsuit filed on behalf of investors who acquired Regeneron Pharmaceuticals, Inc. (“Regeneron ...

Last month, Regeneron resubmitted the BLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in relapsed/refractory (R/R) multiple myeloma following resolution of third-party ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...